Cargando…
Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19
AIMS: SARS-CoV-2 is a single-stranded RNA virus which is part of the ß-coronavirus family (like SARS 2002 and MERS 2012). The high prevalence of hospitalization and mortality, in addition to the lack of vaccines and therapeutics, forces scientists and clinicians around the world to evaluate new ther...
Autor principal: | von Hentig, Nils |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929896/ https://www.ncbi.nlm.nih.gov/pubmed/33660020 http://dx.doi.org/10.1007/s00228-021-03108-x |
Ejemplares similares
-
Evaluation of Platelet Activation by HIV Protease Inhibitors – The HIV-PLA II Study
por: Kann, Gerrit, et al.
Publicado: (2021) -
Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′s main protease
por: Mahdi, Mohamed, et al.
Publicado: (2020) -
Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers
por: Goda, Jayant S., et al.
Publicado: (2016) -
Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition
por: Gimeno, Aleix, et al.
Publicado: (2020) -
Gemcitabine and Nucleos(t)ide Synthesis Inhibitors Are Broad-Spectrum Antiviral Drugs that Activate Innate Immunity
por: Shin, Hye Jin, et al.
Publicado: (2018)